Do you have the patience for the Permian? Should you?
It hasn't exactly been a great few months oil shale producers in the Permian Basin. Shares of Pioneer Natural Resources (PXD), the biggest pure play on Permian oil, closed at $169.97 a share today, August 29, down from $212.31 a share on May 18. That's a decline of...
Adding a buy on shares of Sangamo Therapeutics for Tuesday, September 11, in my Volatility Portfolio
On Monday September 10, I snuck a buy recommendation for shares of Sangamo Therapeutics (SGMO) in just before the 5 p.m. deadline for my daily e-mail update. Here's a full post on the logic for that recommendation. I'd has been a wild ride for shares of biotech...
Adding a put/call trade to my Volatility Portfolio
It's September, the middle month of the most volatile three month period in the investing year (historically on average.) We're in the midst of an emerging market crisis that's being driven by a strong U.S. dollar--and we're looking at the high likelihood of two more...
Selling Incyte calls at $95 now to re-buy after weekend at lower strike
Shares of Incyte (INCY), a member of my Jubak Picks portfolio, have been marching steadily higher in the last couple of weeks. The stock is 19.6% higher since the $61.75 low on August 6. And it's up another 2.06% today, Tuesday, August 28. But the call options I own...
Nektar beats on earnings–more importantly FDA accepts company’s new opioid for review
I'm on vacation through August 26. I'm trying to use this down time to catch up on earnings results that I missed during the very busy second quarter earning season. After the market close on Wednesday, August 8, Nectar Therapeutics (NKTR) reported earnings of $5.33 a...
Rebuying Equinor call options at $25 for my Volatility Portfolio
When  I sold my options on Equinor (EQNR) out of my Volatility Portfolio back on July 18, the idea was to take some profits (I was looking at a better than 50% gain and the shares were trading at $26.42) and to roll the calls with an October 19, 2018 expiration with a...
My August 17 NKTR calls run out of time–selling out of the Volatility Portfolio
The catalysts are out there, as Fox Mulder, might say, but the August 17 call options with a strike of $60 have run out of time. I'm selling today with a 86% loss since I added them on June 6, 2018. Thanks to the huge gains in previous rounds of Nektar options in...
Buying new cobalt player Wheaton Precious Metals in my Volatility Portfolio
Yesterday in Part 3 of my Special Report on "Investing in a Late Cycle Market" I made Wheaton Precious Metals (WPM) one of my "musical chairs" picks. Please note that I could have argued for buying this stock on its exposure to silver and gold. (Gold and silver will...
Nektar up 6.32% today on opioid data presentation
Frankly, my holdings of shares and options on Nektar Therapeutics (NKTR) are driving me nuts. The stock is just so volatile that I can barely stand it even though I'm comfortable with the long-term trajectory of the company's new non-addictive opioid and its leading...
FDA delivers less than half a loaf to INCY and LLY in approving Olumiant
Today the U.S. Food & Drug Administration did finally approve Baricitinib, now known as Olumiant, for the treatment of moderately-to-severely active rheumatoid arthritis. But the approval carries more restrictions than expected. The FDA approved only the 2...Jim’s Stock Alerts
Download Jim’s eBook for Free
